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                         ABSTRACT 
 
Biliary innate immunity is involved in the pathogenesis of cholangiopathies in patients 
with various biliary diseases. Biliary epithelial cells possess an innate immune system 
consisting of the Toll-like receptor (TLR) family and recognize pathogen-associated 
molecular patterns (PAMPs). Recently, regulatory mechanisms by intracellular negative 
regulators including peroxisome proliferator-activated receptor-γ and micro-RNA have 
been clarified. In primary biliary cirrhosis (PBC) and primary sclerosing cholangitis, 
dysregulated biliary innate immunity, namely hyper-responsiveness to PAMPs, is 
associated with the histopathogenesis of cholangiopathy. Moreover, biliary epithelial 
cells produce monocyte chemotactic protein-1 (MCP-1/CCL2) as a result of the innate 
immune response and bile ductules play a role in hepatic fibrosis caused by hepatic 
stellate cells (HSCs). Also, biliary innate immune responses induce the production of 
two chemokines, fractalkine and macrophage inflammatory protein-3α (MIP-3α), 
causing the migration of inflammatory cells and a population of antigen-presenting cell 
found in epithelium, Langerhans cell, and involve chronic cholangitis associated with 
biliary epithelium-specific innate and acquired immunity in PBC.  
 
KEY WORDS : biliary epithelial cell, cholangiopathy, innate immunity, Toll-like 
receptor, chemokine, primary biliary cirrhosis  
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Introduction 
 Infectious agents are involved in various cholangiopathies including 
cholangitis, bile duct loss, and lithiasis as either etiopathological or aggravating factors. 
Several enterobacteria and viruses are speculated to be primary or secondary factors for 
primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), biliary atresia, 
and biliary lithiasis. Such cholangiopathy is closely associated with biliary innate 
immunity and the periductal cytokine network [1-7]. Epithelial cells as well as 
immunocompetent cells such as dendritic cells (DCs) possess pathogen-recognition 
receptors such as Toll-like receptors (TLRs) reflecting the proper micro-environment 
and function of each epithelial cell type. Biliary epithelial cells (BECs, cholangiocytes) 
also possess TLR-related innate immune systems [6, 8-10]. Because no microorganisms 
showing BEC-specific tropism have been identified, an innate immune response 
specific to BEC rather than pathogen-associated molecular patterns (PAMPs) is 
important in the pathogenesis of cholangiopathy. We have previously reviewed the basic 
molecular mechanism of biliary innate immunity in this journal [11]. In this review, we 
attempted to summarize recent progress in the study of the pathophysiological role of 
biliary innate immunity in the mechanisms of cholangiopathy, mainly based on our own 
data (Table 1). 
  
Regulatory system of biliary innate immunity: update 
 Human BECs possess functional PAMP-recognizing receptors including at least 
TLR1-5 (Table 1). These TLRs are distributed throughout the intrahepatic biliary tree in 
normal and diseased human livers, irrespective of anatomical level, implying that BECs 
participate directly in innate immunity and show a prompt response to pathogens 
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without any help from immunocompetent cells [6, 9, 10, 13, 18, 28, 29].  
 Although the luminal surface of the bile duct is continually exposed to PAMPs in 
bile, mainly originating from the intestines, BECs physiologically do not elicit an 
inflammatory response. Tight control of TLR signaling provides tolerance to 
physiological amounts of intestinal endotoxin in bile to avoid constant innate immune 
activation in BECs. This failure to respond to PAMPs, especially LPS, could be due to 
"endotoxin tolerance." In human BECs, IRAK-M and peroxisome proliferator-activated 
receptor γ (PPARγ) are closely associated with the maintenance of biliary homeostasis 
as a regulator of tolerance by attenuating inflammatory signals to commensal PAMPs in 
bile, as summarized in our previous review of this journal [11]. 
 Recently, novel regulatory mechanisms of biliary innate immunity associated 
with the TLR system have been clarified. Micro-RNAs play important roles in a wide 
range of biological events through post-transcriptional suppression of target mRNAs. 
Recent studies indicate Micro-RNA-mediated post-transcriptional pathways to be 
critical to host-cell regulatory responses to microbial infections. Cultured human BECs 
express let-7 family members which post-transcriptionally down-regulate TLR4 
expression and infections of C. parvum decrease the expression of let-7 resulting in the 
up-regulation of TLR4 [16]. Moreover, microRNA-98 and let-7, suppressing 
cytokine-inducible Src homolog 2-containing protein (CIS, a suppressor of cytokine 
signaling family) at the translational level, are expressed in BECs, and LPS and C. 
parvum infections downregulate these micro-RNAs, suggesting the regulation of the 
TLR-mediated biliary innate immune response [17]. 
 In PBC, compared with Th2, a Th1-dominant cytokine milieu is associated with 
the pathogenesis including bile duct injury [30]. BECs possess the receptor for IFN-γ 
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(Th1 cytokine) and IFN-γ up-regulates the expression of TLRs and susceptibility to 
PAMPs in BECs, as mentioned above, impairing the regulation of biliary innate 
immunity. The upregulation of TLR4 and TLR9 in BECs and of TLR3 and type I IFN 
signaling pathways in portal tracts and parenchyma are found in PBC [28, 29, 31]. 
Moreover, IL-4 (Th2 cytokine) and IFN-γ up- and down-regulate the expression of 
PPARγ in cultured human BECs [15, 32]. In PBC liver, PPARγ expression is 
significantly down-regulated in the affected bile ducts as a Th1-dominant periductal 
cytokine milieu [15]. These findings indicate an increased susceptibility to PAMPs, 
suggesting an association with the pathogenesis of cholangiopathy in PBC.  
 Moreover, in PSC, inappropriate biliary innate immune responses to intestinal 
endotoxin and subsequent endotoxin intolerance have been reported to contribute to the 
development and perpetuation of chronic cholangitis [33]. BECs from PSC livers show 
reversibly increased TLR expression and activation of TLR-related intracellular 
signaling. Consecutively, PSC BECs exhibit inappropriate innate immune responses to 
endotoxin and do not develop tolerance after repeated exposure to endotoxin. This 
hyper-responsiveness is probably because of the stimulatory effect of abundantly 
expressed IFN-γ and TNF-α in PSC livers, which stimulate TLR4-mediated endotoxin 
signaling in BECs, leading to increased TLR4-mediated endotoxin incorporation and 
impaired inactivation of the TLR4 signaling cascade.  
 
Hepatic fibrosis and biliary innate immunity 
A major feature of chronic liver diseases, hepatic fibrosis, spreads within portal 
tracts and also periportal areas in patients with hepatitic and cholestatic liver diseases, 
irrespective of etiology. In particular, a fibrogenic cytokine-rich environment caused by 
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inflammation and infection is closely associated with hepatic fibrosis. 
Periportal fibrosis is thought to be associated with the accumulation and 
activation of hepatic stellate cells (HSCs). In damaged liver, HSCs are activated, 
proliferate, and migrate into the injured area in response to the chemoattractive effects 
of chemokines and are considered the most important effecter cells associated with 
fibrogenesis in hepatic parenchyma including the interface between portal tracts and 
periportal hepatocytes, and the fibrous enlargement of portal tracts and fibrous 
extension from portal areas are closely associated with activated HSCs and their 
transformed version, myofibroblasts. Then, HSCs, particularly activated HSCs, migrate 
into damaged areas in response to a chemokine, secreting monocyte chemotactic 
protein-1 (MCP-1/CCL2) which attracts monocyte/macrophages [34]. 
BECs directly promote fibrogenesis by a number of mechanisms including the 
synthesis of matrix constituents and the release of fibrogenic cytokines such as MCP-1, 
platelet-derived growth factor, TGF-β, connective tissue growth factor (CTGF), and 
endothelin-1 [35]. Moreover, only the expression of MCP-1 positively regulated by 
TLR ligands (PAMPs) occurs in an NF-κB-dependent manner, suggesting that the 
biliary innate immune response is a critical trigger of MCP-1 production. 
 Proliferating bile ductules are thought to be part of a non-specific reaction in 
various hepatobiliary diseases, and bile ductules located between interlobular bile ducts 
in portal tracts and bile canaliculi in hepatocytes are frequently increased in number 
under a variety of pathologic conditions of the liver and take part in hepatic fibrosis and 
the progression of hepatobiliary diseases [26, 36, 37]. MCP-1 is expressed in bile 
ductules in areas of interface hepatitis (Fig.1), whereas normal livers lacked these 
findings. Moreover, α-smooth muscle actin (α-SMA)-positive activated HSCs 
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(myofibroblasts) are accumulated around MCP-1-expressing bile ductules (Fig.1), 
suggesting that MCP-1 derived from BECs consisting of bile ductules plays a role in the 
chemoattraction of HSCs. Because the interface areas are rich in several cytokines 
caused by immune-mediated (necro)inflammatory reactions against virus-infected 
hepatocytes and bile-derived PAMPs, BECs in bile ductules could produce MCP-1, 
particularly, via biliary innate immunity, suggesting that biliary innate immunity 
directly plays an important role in the recruitment of HSCs to interface areas and the 
activation of HSCs resulting in the progression of periportal fibrosis.  
 
Fractalkine and innate immunity in PBC 
 PBC mainly affects middle-aged females, and histologically, the interlobular 
bile ducts are primarily damaged and show characteristic findings such as chronic 
nonsuppurative destructive cholangitis (CNSDC) followed by progressive bile duct loss 
[38]. There is considerable evidence that the damage of bile ducts is mediated by 
autoreactive or cytotoxic T cells [39], and molecular mechanisms of the migration of 
pathogenic T cells around or within bile ducts have gradually been clarified.   
 There have been several reports that bacterial components such as 
lipopolysaccharide (LPS) and DNA fragments are detectable in pathologic bile of 
patients with PBC [5, 6], and also endotoxin and lipoteichoic acids abnormally 
accumulate in or around the intrahepatic bile ducts of PBC [5-7, 40, 41]. Unusual 
immune responses to these infectious agents or their components are now suspected to 
underlie the etiopathogenesis of PBC [42-45].  
 The chemokine-adhesion molecule, fractalkine (CX3CL1), plays an important 
role in the migration of leukocytes to target sites under physiological as well as 
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pathological conditions. Unlike other chemokines, fractalkine is expressed as a 
membrane-bound form on cells and also can be shed by ADAM10 or ADAM17 as a 
soluble chemotactic form. Vascular endothelial cells express fractalkine and its soluble 
form is a potent chemoattractant for CD16+NK cells, CD8+ cytotoxic T cells, CD4+T 
cells, γδT cells, monocytes, mature macrophages, and mucosal DC cells, expressing its 
receptor (CX3CR1). The level of soluble fractalkine is significantly elevated in the sera 
of PBC patients and also in situ expression of fractalkine in small bile ducts, particularly 
damaged bile ducts, is upregulated in PBC [24] (Fig.2), suggesting that fractalkine is an 
important mediator associated with the continuous portal, particularly periductal, 
inflammation of PBC.  
   Upregulation of fractalkine expresion in BECs is induced by PAMPs including 
LPS, suggesting that the dysregulated biliary innate immunity against commensal or 
pathological PAMPs is closely associated with the production of fractalkine in BECs 
and that secreted soluble fractalkine may be involved in the chemoattraction of 
infiltrating cells expressing CX3CR1 around these pathological bile ducts and in the 
recruitment of biliary intraepithelial leukocytes. Moreover, the up-regulation of 
fractalkine expression in BECs is promoted by TLR3 ligand (poly(I:C)), via activated 
monocytes through direct contact and the secreation of TNF-α by monocytes [25]. 
Intraepithelial lymphocytes in damaged bile ducts of PBC patients contain a 
significantly higher percentage of CD8+ T cells and show strongly increased cytolytic 
activity against epithelial-derived target cells [46]. Then, CX3CR1-positive leukocytes 
invade into bile ducts by engaging fractalkine, thereby causing cholangitis including 
CNSDC [25].  
   In addition to PBC, fractalkine is associated with the chronic inflammation in 
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other diseases including rhematoid arthritis and inflammatory bowel disease. Recently, 
an anti-fractalkine monoclonal antibody has been reported to almost completely 
suppress the clinicopathological activities in inflammatory bowel disease models [47]. 
Therefore, fractalkine-CX3CR1 signaling might be a molecular target for the treatment 
of PBC. 
 
Antigen-presenting cells and biliary innate immunity in PBC  
 The presence and response to mitochondrial autoantigen(s) of autoreactive T 
cells [39] is believed to require interaction with professional antigen-presenting cells 
(APCs) such as DCs. DCs are generally classified into myeloid DCs (mDCs) and 
plasmacytoid DCs (pDCs) and reside in tissues of most organs under normal conditions. 
In the periphery, immature DCs such as Langerhans cells (LCs, a population of DCs 
only found in epithelia) capture antigens and, under the influence of inflammatory 
stimuli, subsequently migrate. The presence of APCs in biliary trees is likely important 
to the bile duct-specific autoimmunity in PBC. In the inflammed bile ducts, several DCs 
including immature DCs [48], S-100+ DCs,[49] and LCs[50, 51] are found, indicating a 
role in the initiation of inflammatory responses in cases of PBC. Moreover, periductal 
DCs are mostly mDCs and the major representative type of mDCs, Langerin+ LCs, are 
attached to or embedded in the damaged bile ducts of PBC patients (Fig.3) [23], 
suggesting that LCs existing around and within bile ducts play an important role as 
APCs presenting bile duct-derived autoantigens. 
Because LCs possess chemokine receptors (CCR4 and CCR6), ligands of these 
receptors including CCL17, CCL22, and MIP-3α (CCL20) could cause LCs to migrate. 
Among them, MIP-3α plays a central role in recruiting LC precursors into the 
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epithelium during inflammation and also an important role in the pathogenesis of 
ulcerative colitis [52, 53]. In PBC, MIP-3α-expressing BECs are frequently found in the 
damaged bile ducts accompanying Langerin+ LCs, suggesting that the BECs producing 
MIP-3α directly play an important role in the migration of LCs in biliary layers. 
Moreover, the expression of MIP-3α is selectively restricted at sites of inflammation 
including cholangitis in PBC (Fig.3) and bile duct-related acquired immunity is 
speculated to be closely associated with the periductal cytokine milieu and biliary innate 
immunity [6, 9, 15, 24, 30]. Because human BECs possess receptors for some cytokines 
(IL-1β, IL-6, IL-4, IFN-γ, TNF-α, and IL-17) as well as TLRs [9, 21], they could show 
a response to these cytokines as well as PAMPs and induce various immunological 
reactions. IL-17 and two inflammatory cytokines (IL-1β and TNF-α) significantly 
upregulate the expression of MIP-3α in human BECs. IL-17-positive cells (namely 
Th17 cells) are accumulated around the damaged bile ducts in PBC and the expression 
of IL-1β and TNF-α was increased in damaged bile ducts including CNSDC of PBC 
patients [20, 21]. Therefore, the production of MIP-3α in PBC is closely associated with 
periductal cytokines including IL-1β, TNF-α, and IL-17. In addition to these cytokine 
milieus, the damaged bile ducts and/or portal tracts show an increased susceptibility to 
PAMPs and enhanced production and secretion of innate inflammatory mediators in 
PBC [15, 29]. PAMPs directly induce the production of MIP-3α in human BECs [23]. 
Therefore, LCs existing around or within biliary epithelial layers are induced to migrate 
via BEC-derived MIP-3α expression evoked via a PBC-specific periductal cytokine 
milieu and biliary innate immunity and are important as biliary epithelium-specific 
APCs in the development of acquired immunity and the aggravating and continuous 
cholangitis in PBC. 
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Conclusion and perspectives 
 Biliary innate immunity consisting of an bile duct-specific system is 
important for the mucosal immunity in intrahepatic and extrahepatic bile ducts and 
also associated with the pathogenesis of several cholangiopathies in biliary diseases as 
well as defense against microbial infections. We speculate that biliary innate immunity 
is solely associated with the etiology of biliary diseases as the initial event and that the 
presence of causative microorganisms is not necessary in the pathogenesis of 
cholangiopathy caused by a subsequent acquired immunity. It is mandatory to 
understand the molecular basis underlying the immunophysiology and 
immunopathology of cholangiopathy in terms of innate as well as acquired immunity. 
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Summary of biliary innate immunity 
 
---------------------------------------------------------------------------------------------------------- 
  Receptors recognizing PAMPs 
TLRs   
   TLR1 [12, 13] 
   TLR2 [9, 12, 13]  
   TLR3 [9, 12-14] 
   TLR4 [6, 9, 12, 13] 
   TLR5 [9, 12, 13]  
   TLR6 [9, 12, 13]  
   TLR7 [12] 
   TLR8 [12]  




Negative regulators of TLR signalings 
IRAK-M [8] 
PPAR-γ [15] 
micro-RNA [16, 17] 
 
Antibiotics, cytokine, and chemokines produced via biliary innate immunity 
defensin [18] 
IFN-1 [10] 
TNF-α [19, 20] 
IL-6 [13, 20, 21] 
IL-1β [21]  
IL-23 p19 [21] 
MCP-1[13, 22] 
MIP-3α [23] 
Fractalkine (CX3CL1 ) [24, 25] 




Parentheses denote reference numbers. 
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Figures and legends 
 
  




Fig.1  Immunohistochemistry for MCP-1 and αSMA. A and B; HCV-related chronic 
viral hepatitis. Proliferating bile ductules at the interface of periportal areas 
express MCP-1(A, arrows) and αSMA-positive cells showing hepatic stellate 
cell (HSC) morphology are found in the same area (B, arrows). C; primary 
biliary cirrhosis. MCP-1-positive proliferating bile ductules are found (arrow).  
  





A                                   B 
Fig.2  Immunohistochemistry for fractalkine. Primary biliary cirrhosis. Fractalkine is 
expressed in damaged bile duct (arrow in A) and periductal inflammatory cells 
in portal tracts and intrasinusoidal cells, probably Kupffer cells, in parenchyma. 
B is a higher magnification of A. 
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A                                   B 
Fig.3.  Detection of Langerhans cells (LCs) and macrophage inflammatory protein-3α 
(MIP-3α) in liver sections. (A) Langerin+ LCs are found around and within bile 
ducts showing cholangitis in primary biliary cirrhosis (PBC). (B) MIP-3α is 
expressed in infiltrating mononuclear cells and the damaged bile ducts (arrows) 
in PBC.  
 
 
 
